Advances in therapeutics for liver metastasis from colorectal cancer

doi:10.4251/wjgo.v2.i10.380

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 10

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2254)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

276

HTML

1807

Tables (1-1)

171

Sum=2254

Oct 15, 2010 (publication date) through May 6, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastrointest Oncol. Oct 15, 2010; 2(10): 380-389
Published online Oct 15, 2010. doi: 10.4251/wjgo.v2.i10.380

Table 1 Resection rates and long-term outcomes following systemic chemotherapy in patients with unresectable metastatic colorectal cancer

Study	Treatment (n)Median survival (mo)	Resection rate (%) 5-year survival All/R0 (%)
Bismuth et al[5]	5-FU/LV ± oxaliplatin (330) NA	16/14 40^a/-
Giacchetti et al[25]	5-FU/LV + oxaliplatin (151) 48^a/NR^b	51/38 50^a/58^b
Wein et al[26]	5-FU/LV (53) NA	17/11 NA
Zelek et al[27]	5-FU/LV + irinotecan + HAI (31) -/20.2^b (PFS)	35/29 -/65^b (3-year survival)
Adam et al[7]	5-FU/LV + oxaliplatin and/or irinotecan (1104) 39^a/-	12.5/10.9 33^a/-
Tournigand et al[28]	FOLFIRI (109) 47^a/-	9/7 NA
	FOLFOX4 (111) NR	22/14 NA
Pozzo et al[8]	FOLFIRI (40) 14.3 (DFS)^a/-	40/32.5 NA
Alberts et al[9]	FOLFOX4 (42) NA	40/33 NA
Seium et al[29]	5-FU/LV + oxaliplatin + irinotecan (30) NA	7/- NA
Folprecht et al[30]	5-FU/LV + irinotecan + cetuximab (21) NA	-/19 NA
Masi et al[31]	FOLFOXIRI, simplified FOLFOXIRI (74) -/36.8^b	-/26 -/37^b (4-year survival)
Tournigand et al[32]	FOLFOX4 (311) 38.9^a/-	17.7/11.3 NA
	FOLFOX7 (309) 43.0^a/-	15.2/9.4 NA
Folprecht et al[33]	FOLFOX + cetuximab (53) NA	49/38 NA
	FOLFIRI + cetuximab (53) NA	43/30 NA

^aResected patients only; ^bR0 resection only. 5-FU/LV: 5-Fluorouracil/leucovorin; NA: Not available; NR: Not reached; HAI: Hepatic arterial infusion; PFS: Progression-free survival; FOLFIRI: 5-Fluorouracil, leucovorin, and irinotecan; FOLFOX: 5-Fluorouracil, leucovorin, and oxaliplatin; DFS: Disease-free survival; FOLFOXIRI: 5-Fluorouracil, leucovorin, oxaliplatin, and irinotecan.

Citation: Kobayashi A, Miyagawa S. Advances in therapeutics for liver metastasis from colorectal cancer. World J Gastrointest Oncol 2010; 2(10): 380-389
URL: https://www.wjgnet.com/1948-5204/full/v2/i10/380.htm
DOI: https://dx.doi.org/10.4251/wjgo.v2.i10.380